What happens when you stop taking GLP-1, week by week

TLDR. When you stop a GLP-1, appetite begins returning within 1 to 2 weeks. Most patients regain about two-thirds of lost weight within 12 months, per the STEP-1 extension and STEP-5 maintenance data. Lean mass regains faster than fat mass, which is a metabolic problem. The patients who stop without regain are rare and share common traits: they reach their goal weight slowly, build sustained resistance training, and either taper the medication or microdose at maintenance. This walks through the week-by-week biology, the trial evidence and the three honest options when you want to come off.

Week 1: the medication is still working

Semaglutide has a half-life of about 168 hours (one week). Tirzepatide is similar at about 120 hours. That means a week after your last dose, you still have roughly 50 percent of the drug active in your system.

What you will notice in week 1: nothing. Appetite is suppressed, food noise is quiet, satiety arrives at small portions. The medication is doing what it was doing the previous month.

Week 2 to 3: appetite begins to return

By two to three weeks post-stop, drug levels have dropped to 12 to 25 percent of steady state. The GLP-1 receptor is still partially occupied, but signaling is weaker.

What patients report:

• Hunger returns between meals, not just at meal times
• Food noise, the intrusive thoughts about food the medication had silenced, comes back
• Portion sizes that felt large at month 6 now feel normal
• Gastric emptying speeds back up; meals leave the stomach faster, hunger arrives sooner

Weight at this point is usually stable from your stop date. The behavioral changes have not yet caught up with the biology.

Week 4 to 6: caloric intake starts climbing

By a month off the drug, plasma levels are essentially zero. Receptor signaling returns to baseline. The hunger and satiety signals you had before starting the medication are back at full volume.

Two things happen in parallel. First, your appetite is now driving you toward your pre-medication food intake. Second, your metabolic rate has adapted downward to your new lower body weight, which is normal weight-loss biology. The result: even matching your pre-medication eating habits, you are now in a small caloric surplus rather than balance.

Typical weight movement at week 6: zero to 3 pounds regained. Most of it is glycogen and water, the inverse of the rapid early loss you saw in month 1 of starting the medication.

Week 7 to 12: the regain curve steepens

Months 2 and 3 post-stop are when the actual fat regain begins. The STEP-1 extension trial, published in Diabetes, Obesity and Metabolism in 2022, followed patients for 1 year after stopping semaglutide. The curve showed:

• Months 1 to 3 post-stop: 30 percent of lost weight returns, mostly water and glycogen plus initial fat
• Months 4 to 6: another 20 percent returns, dominated by fat regain
• Months 7 to 12: another 15 percent returns, slower as energy balance stabilizes
• Total at 12 months: 65 percent of lost weight regained on average

SURMOUNT-1 has not yet published a comparable 1-year off-treatment extension, but the SURMOUNT-4 "withdrawal" arm of tirzepatide showed similar patterns at 88 weeks: patients who stopped regained 14 percent of body weight on average, while patients who continued lost an additional 5 percent.

The lean-mass problem

Here is the part most patients are not told. When you lose weight on a GLP-1, about 25 to 40 percent of the loss is lean mass, per DXA substudies of STEP-1 and SURMOUNT-1. When you regain after stopping, the regain is disproportionately fat, not lean mass.

The 2024 paper by Wadden and colleagues in JAMA on weight-cycling after anti-obesity medication discontinuation showed regain composition averaged 75 to 85 percent fat, with only 15 to 25 percent lean tissue. Translation: a patient who lost 30 pounds (20 fat, 10 lean) and then regained 20 pounds may end up with 16 pounds of new fat and 4 pounds of new lean. The body fat percentage is now higher than the starting state.

This matters clinically because higher body fat percentage at the same scale weight worsens metabolic markers, insulin sensitivity and cardiovascular risk. The patients who regain to their starting weight are not back where they started; they are metabolically worse.

See our muscle-loss article for what to do during active treatment to minimize the loss that comes back as fat later.

The metabolic adaptation research

The mechanism behind the regain curve is metabolic adaptation, a term that covers two related processes:

1. Adaptive thermogenesis. When body weight drops, resting metabolic rate falls by more than the loss of lean mass alone would predict. The body is biased toward energy conservation at the new lower weight. The classic study, Rosenbaum and Leibel 2010 in International Journal of Obesity, showed a 300 to 400 kcal/day reduction in energy expenditure at a 10 percent weight loss, sustained for years.
2. Hormonal counter-regulation. Leptin drops, ghrelin rises, peptide YY drops. The body's hunger-and-satiety hormones all shift to drive intake up and expenditure down. GLP-1 medications partially overrode these counter-regulatory signals; stopping the medication unmasks them.

The honest takeaway: regain after stopping anti-obesity medication is not a willpower failure. It is the underlying biology of obesity reasserting itself once the pharmacological override is removed.

Who should actually stop

Three patient profiles where stopping is reasonable:

1. Pregnancy or trying to conceive

Both Wegovy and Zepbound carry pregnancy-Category warnings (avoid in pregnancy, stop at least 2 months before attempted conception per the labels). Pregnancy planning is a clear, time-limited stop. Regain during pregnancy is expected and managed by the OB.

2. Pre-surgical and perioperative

GLP-1s delay gastric emptying, which raises aspiration risk under general anesthesia. The 2023 American Society of Anesthesiologists guidance recommended holding GLP-1s for 1 week before elective surgery (weekly drugs). This is also a time-limited stop.

3. Patients who hit a low BMI and want a maintenance break

The least clean indication. Some patients who reach a healthy BMI (under 25) want to test whether they can hold the loss without medication. The honest expectation is regain to about a BMI 27 to 28 at 12 months. If that is acceptable, a planned stop with a structured restart protocol (described in the maintenance guide) is reasonable.

The tapering option

Tapering rather than abrupt stopping is increasingly recommended in 2026, though randomized-trial evidence is thin. The logic is straightforward: instead of going from 2.4 mg semaglutide weekly to zero, you step down to 1.7, then 1.0, then 0.5, then 0.25, each step for 6 to 8 weeks. Total taper window: 6 to 8 months.

The observational data from telehealth programs running structured tapers (Form Health, Knownwell) suggests taper patients regain less weight over the first 12 months than abrupt-stop patients, by roughly 5 to 8 percentage points of body weight. The taper does not prevent regain. It slows it and seems to preserve more lean mass.

If you are stopping by patient choice (not pregnancy or surgery), tapering is the safer move. Discuss the protocol with your prescriber.

The microdosing maintenance approach

The third option, gaining traction in 2025-2026, is microdose maintenance: stay on the medication indefinitely at a much lower dose, typically 0.25 to 0.5 mg semaglutide weekly (versus the 2.4 mg therapeutic dose).

The argument: the appetite-suppressive effect at sub-therapeutic doses is partial but real, the cost drops substantially and the side-effect burden almost disappears. Some patients hold their goal weight on a 10-percent maintenance dose. Evidence is observational and not yet randomized.

See our microdosing evidence article for the published case-series data and the dose-response curves.

What the SELECT data adds

The SELECT trial (semaglutide in cardiovascular disease, NEJM 2023) followed 17,604 patients for a median of 40 months. The intent-to-treat analysis showed sustained 9.4 percent weight loss at 4 years among patients who stayed on semaglutide. The implication: patients who stay on the drug long-term maintain most of their loss. The discontinuation arms of SELECT showed the standard regain pattern.

For patients with established cardiovascular disease, the SELECT data also showed a 20 percent reduction in MACE (major adverse cardiovascular events) on continued semaglutide. Stopping the medication forfeits both the weight-management benefit and the cardiovascular benefit. See our SELECT trial deep-dive.

What to actually do if you want to stop

Three honest paths:

1. If pregnancy or surgery is the reason: stop on the prescriber's schedule (typically 1 to 2 weeks pre-event), expect some regain, restart after the event clears.
2. If cost is the reason: microdose at the lowest dose your prescriber will allow before stopping entirely. Compounded semaglutide at 0.25 mg weekly through programs like Mochi can be $50 to $80 per month, which keeps the maintenance benefit at a fraction of the active-treatment cost.
3. If you are tired of being on medication: taper over 6 months. Build sustained resistance training and high protein intake during the taper. Accept that regain to BMI 27 to 28 from a treatment nadir of BMI 24 is the most likely outcome.

What does not work: abrupt stopping at goal weight, expecting behavioral changes alone to hold the loss. The trial data is unambiguous on this point.

FAQ

How long after stopping until I see weight regain on the scale?

Two to four weeks for most patients. The first 2 to 5 pounds are water and glycogen returning as caloric intake normalizes. Sustained fat regain begins around week 6 to 8 and accelerates through months 3 to 6 post-stop.

Does the regain happen even if I keep eating the same as on the medication?

Partially yes. Metabolic adaptation has lowered your resting expenditure, so the same caloric intake that maintained your reduced weight on the medication now produces a small surplus. Most patients also drift caloric intake upward as appetite returns, compounding the surplus. The trial extension data assumes patients eat to satiety, which is the realistic case.

Can I prevent regain by exercising harder?

Resistance training reduces regain meaningfully and preserves lean mass during regain. Cardio alone does not reverse the appetite or metabolic-adaptation drivers. The combination (resistance training plus moderate cardio plus high-protein intake) gets you the best outcomes the literature supports, but does not eliminate regain.

Is microdose maintenance covered by insurance?

Rarely. Insurance plans typically cover the therapeutic dose (1.7 mg or 2.4 mg semaglutide, 5 mg through 15 mg tirzepatide). A 0.25 mg maintenance dose is below the FDA label and is considered off-label by most plans. The microdose route is usually cash-pay, often through compounded prescriptions.

What if I stopped a year ago and want to restart?

Restart at the lowest titration dose (0.25 mg semaglutide or 2.5 mg tirzepatide) and re-titrate fully, even if you previously reached the maximum dose. Restart side effects are typically similar to first-start side effects; the gastrointestinal tract does not retain tolerance once the drug has cleared. Discuss the restart schedule with your prescriber; see our titration guide for the standard protocol.